Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinya Omoto

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2019
Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic OutcomesNobuo Hirotsu, Hiroki Sakaguchi, Chisako Sato, et al.
Microbiology and Immunology|January 9, 2003
Double-stranded nef RNA interferes with human immunodeficiency virus type 1 replicationTakuya Yamamoto, Shinya Omoto, Masaaki Mizuguchi, et al.
Vaccine|June 23, 2022
Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority studyMasaharu Shinkai, Takuhiro Sonoyama, Akari Kamitani, et al.
Vaccine|July 3, 2026
Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled studyTakashi Nakano, Satoshi Iwata, Kazunori Oishi, et al.
Vaccine|January 31, 2025
A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferretsMasayuki Hashimoto, Kenichiro Tsujii, Hitomi Nakajima-Yoshida, et al.
Communications Biology|September 28, 2022
Assessing the fitness of a dual-antiviral drug resistant human influenza virus in the ferret modelHarry L Stannard, Edin J Mifsud, Steffen Wildum, et al.
The Journal of Infectious Diseases|July 17, 2019
Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated InfluenzaTakeki Uehara, Frederick G Hayden, Keiko Kawaguchi, et al.
Frontiers in Immunology|March 9, 2023
A-910823, a squalene-based emulsion adjuvant, induces T follicular helper cells and humoral immune responses <i>via</i> α-tocopherol componentYuya Yoshioka, Kouji Kobiyama, Tomoya Hayashi, et al.
Chemistry, an Asian Journal|February 10, 2011
A strategy for neuraminidase inhibitors using mechanism-based labeling informationHiroshi Hinou, Risho Miyoshi, Yasuaki Takasu, et al.
Vaccine|December 26, 2022
Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adultsTakuhiro Sonoyama, Satoshi Iwata, Masaharu Shinkai, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2019
Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic OutcomesNobuo Hirotsu, Hiroki Sakaguchi, Chisako Sato, et al.
Microbiology and Immunology|January 9, 2003
Double-stranded nef RNA interferes with human immunodeficiency virus type 1 replicationTakuya Yamamoto, Shinya Omoto, Masaaki Mizuguchi, et al.
Vaccine|June 23, 2022
Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority studyMasaharu Shinkai, Takuhiro Sonoyama, Akari Kamitani, et al.
Vaccine|July 3, 2026
Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled studyTakashi Nakano, Satoshi Iwata, Kazunori Oishi, et al.
Vaccine|January 31, 2025
A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferretsMasayuki Hashimoto, Kenichiro Tsujii, Hitomi Nakajima-Yoshida, et al.
Communications Biology|September 28, 2022
Assessing the fitness of a dual-antiviral drug resistant human influenza virus in the ferret modelHarry L Stannard, Edin J Mifsud, Steffen Wildum, et al.
The Journal of Infectious Diseases|July 17, 2019
Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated InfluenzaTakeki Uehara, Frederick G Hayden, Keiko Kawaguchi, et al.
Frontiers in Immunology|March 9, 2023
A-910823, a squalene-based emulsion adjuvant, induces T follicular helper cells and humoral immune responses <i>via</i> α-tocopherol componentYuya Yoshioka, Kouji Kobiyama, Tomoya Hayashi, et al.
Chemistry, an Asian Journal|February 10, 2011
A strategy for neuraminidase inhibitors using mechanism-based labeling informationHiroshi Hinou, Risho Miyoshi, Yasuaki Takasu, et al.
Vaccine|December 26, 2022
Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adultsTakuhiro Sonoyama, Satoshi Iwata, Masaharu Shinkai, et al.
Pageof 4